27th May 2026 FY25 Annual General Meeting Disclaimer FY25 Annual General Meeting 2 The following material is for general information purposes only and should not be relied on for the making of any investment decision. Any investment in Elixinol Wellness Limited ACN 621 479 794 (Elixinol Wellness) is subject to a number of investment risks including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Elixinol Wellness nor any other entity or person in or associated with the Elixinol Wellness group of companies guarantees any return (whether capital or income) or generally the performance of Elixinol Wellness or the price at which its securities may trade. In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Elixinol Wellness securities. This presentation is not exhaustive of all of the information a potential investor, or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act. This presentation does not take into account any specific objectives, financial situation or needs of investors. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk. This presentation may contain "forward-looking statements" which are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are intended to identify forward looking statements. Any forward-looking statements in this presentation should be considered “at-risk statements” - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors that may lead to actual results differing from any forward-looking statement. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof and Elixinol Wellness does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. In addition, the past performance of Elixinol Wellness cannot be assumed as indicative of the future performance. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined in this Presentation. Neither Elixinol Wellness nor any of its advisers, agents or employees make or give any express or implied representation, warranty or guarantee that the information contained in this presentation or otherwise supplied by or on behalf of Elixinol Wellness is complete or accurate or that it has been or will be audited or independently verified, or that reasonable care has been or will be taken in compiling, preparing or furnishing the relevant information. Elixinol does not take any responsibility for any inference, interpretation, opinion or conclusion that any person may draw or form from this presentation. To the maximum extent permitted at law, Elixinol Wellness and all of its representatives, directors, partners, employees or professional advisers exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), they do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this Presentation or any accompanying, previous or subsequent material or presentation. This Presentation is current as at 27th May 2026. Welcome and Introduction by the Chair FY25 Annual General Meeting New Executive management team with broad industry experience CEO and CFO appointed in FY25 Adam Dimitropoulos Chief Financial Officer Natalie Butler Executive Director & CEO Gavin Evans Non-exec Chair 25 years finance experience, previous positions include CFO at MS Pharma, VP FPA at Stada, Finance & Ops at Amneal, and VP Finance at Actavis 25 years industry experience, previous positions include GM Tom Organics, GM Marketing TSN and L’Oreal International business leader with senior investment banking experience in London and a track record of building food and wellness businesses in Australia, now Chair of EXL. Accomplished Non-Executive Director with 20+ years investment banking experience, holding board roles across FMCG, resources, fintech and not-for-profit, including Chair of Kalgoorlie Gold Mining and Director of Pioneer Credit. 4 Pauline Gately Non-exec Director FY25 Annual General Meeting Agenda 1. Welcome 2. Format of the Meeting 3. Voting & Poll Procedures 4. Chair Address 5. CEO Presentation 6. Q&A Session - Operational 7. Formal Business 8. Q&A Session – Formal Business 9. Poll & Meeting Close 5 FY25 Annual General Meeting Voting & Poll Procedures FY25 Annual General Meeting 6 Written Question Procedure FY25 Annual General Meeting 7 Audio Question Procedure FY25 Annual General Meeting 8 Voting Procedure FY25 Annual General Meeting 9 Chair Address 10 FY25 Annual General Meeting Elixinol Wellness is a diversified health and nutrition platform built for longevity and everyday wellness Hemp Foods Australia Mt Elephant Soul Seeds Nutrition The Healthy Chef Elixinol USA Supplements Australian Primary Hemp The Super Food Co Superfoods 11 Diversified distribution channels to both B2B and B2C Retail partners, direct to consumer through e-commerce and white label products 12 12 Healthy Savoury Snacking 12 12 Repositioned for sustainable growth in FY26 and beyond ✓ Sharper strategic focus ✓ Higher margin revenue ✓ Higher margin e-commerce sales of The Healthy Chef, up 25% YoY in Q1 FY26 ✓ Improved gross margin ✓ 45% gross margin in Q1 FY26, up 8 percentage points YoY ✓ Structurally lower cost base, with operating expenses in Q1 FY26 down 29% YoY ✓ Second consecutive quarter of underlying cash flow positive in Q1 FY261 ✓ National rollout of The Healthy Chef premium product range into Priceline stores ✓ Multiple short-term catalysts, including strong revenue outlook in Q2 and beyond Strategic shift to higher margin categories and channels 13 1 Underlying operating cash flow excludes finance costs, payments for income taxes and other items (out of cycle payments and non-recurring items). Results are unaudited and subject to review. Elixinol has a bold, ambitious vision for a healthy food roll-up... 14 To build a portfolio of premium- branded health food assets, with Australian manufacturing capabilities and global growth potential. 14 CEO PRESENTATION FY25 Annual General Meeting 15 Margin Expansion FY25 was a year of operational reset and strategic repositioning ✓ Simplifying the business structure ✓ Reducing operational complexity ✓ Lowering the cost base ✓ Shifting toward higher-margin categories and channels Scalable platform 16 What We Focused On FY25 Performance $15.5m FY25 Revenue +3.6% year-on-year 163% E-commerce Growth $4.3m in FY25 42% Exit Gross Margin 39% full-year average 30% Opex Reduction Q4 FY25 vs Q4 FY24 Commercial Momentum 17 Retailers and Partners Are Backing Our Core Platforms Innovation-led expansion into everyday wellness categories Three new products launching into 800+ Coles stores in Q2 National Priceline rollout across ~410 stores from Q3 FY26 No 1 in hemp market Premium wellness positioning supporting higher-margin growth Contracted hemp supply supporting recurring revenue visibility into 2027 Market-leading hemp platform, supplying hemp for Coles, Costco & Macro Momentum Is Building ✓ 45% gross margin achieved in Q1 FY26 • Reflecting improved revenue mix, pricing discipline and operational efficiencies ✓ Retail expansion validating innovation strategy • Priceline rollout and expanded ranging across Coles and Metcash supporting brand momentum ✓ Structurally lower cost base improving leverage • Operating expenses reduced 29% YoY in Q1 FY26 ✓ Positioned within attractive long-term wellness growth categories Foundations now in place to support scalable growth 18 Q&A Session (Company Operations) FY25 Annual General Meeting 19 Formal Business FY25 Annual General Meeting 20 Receipt and Consideration of Accounts and Reports 21 “To receive and consider the Financial Report, the Directors’ Report, and the Independent Auditor’s Report of the Company for the financial year ended 31 December 2025 (the Reports). “ Further Information •Please note there is no requirement for a resolution in relation to the receipt and consideration of Accounts and Reports. FY25 Annual General Meeting Resolution 1: Adoption of Remuneration Report 22 To consider and, if thought fit, pass the following resolution as an ordinary resolution of the Company: “That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company’s Annual Report for the year ended 31 December 2025.” In Favour Against Proxy’s Discretion Abstain 92,725,345 174,139 17,342,191 265,538 84.11% 0.16% 15.73% - Further Information •The Board encourages all eligible shareholders to cast their votes in favour of this Resolution. •The Chair will vote undirected proxies for this Resolution. •The Remuneration Report can be found on pages 17 to 25 of the 2025 Annual Report. •Voting restrictions apply, as set out in the Notice of Meeting. FY25 Annual General Meeting Resolution 2: Election of Director – Gavin Evans 23 To consider and, if thought fit, pass the following resolution as an ordinary resolution of the Company: “That for the purposes of clause 6.1 of the Company’s Constitution, ASX Listing Rule 14.4 and for all other purposes Mr Gavin Evans, who retires in accordance with clause 6.1(e) of the Company’s Constitution and, being eligible for election, be elected as a Director of the Company." In Favour Against Proxy’s Discretion Abstain 100,558,546 30,187 17,719,867 3,030 84.99% 0.03% 14.98% - Further Information •The Board (with Mr Evans abstaining in his capacity as director) recommends that Shareholders vote in favour of this Resolution. •The Chair will vote undirected proxies for this Resolution. •Details of the experience and qualification of Mr Evans are set out on page 9 of the Explanatory Statement to the Notice of Meeting. FY25 Annual General Meeting Resolution 3: Re-election of Director – Pauline Gately 24 To consider and, if thought fit, pass the following resolution as an ordinary resolution of the Company: “That for the purposes of clause 6.1 of the Company’s Constitution and for all other purposes, Ms Pauline Gately, who retires in accordance with clause 6.1(f) of the Company’s Constitution and, being eligible for election, be elected as a Director of the Company." In Favour Against Proxy’s Discretion Abstain 100,677,631 68,791 17,346,269 218,939 85.25% 0.06% 14.69% - Further Information •The Board (with Ms Gately abstaining in her capacity as director) recommends that Shareholders vote in favour of this Resolution. •The Chair will vote undirected proxies for this Resolution. •Details of the experience and qualification of Ms Gately are set out on page 11 of the Explanatory Statement to the Notice of Meeting. FY25 Annual General Meeting Resolution 4: Approval of proposed issue of Shares and/or Options under Proposed Capital Raising 25 To consider and, if thought fit, pass the following resolution as an ordinary resolution of the Company: “That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of up to 400,000,000 Shares and up to 800,000,000 Options (or any combination thereof), on the terms and conditions described in the Explanatory Statement." In Favour Against Proxy’s Discretion Abstain 92,828,930 277,729 17,350,445 50,109 84.04% 0.25% 15.71% - Further Information •The Board recommends that Shareholders vote in favour of this Resolution. •The Chair will vote undirected proxies for this Resolution. •Voting restrictions apply, as set out in the Notice of Meeting. FY25 Annual General Meeting Resolution 5: Approval of proposed issue of Convertible Notes under Proposed Capital Raising 26 To consider and, if thought fit, pass the following resolution as an ordinary resolution of the Company: “That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of up to 2,000,000 Convertible Notes (and any Shares issued upon conversion of those Convertible Notes), on the terms and conditions described in the Explanatory Statement." In Favour Against Proxy’s Discretion Abstain 92,828,464 278,879 17,349,281 50,589 84.04% 0.25% 15.71% - Further Information •The Board recommends that Shareholders vote in favour of this Resolution. •The Chair will vote undirected proxies for this Resolution. •Voting restrictions apply, as set out in the Notice of Meeting. FY25 Annual General Meeting Resolution 6: Approval of proposed issue of new Shares, Options and/or Convertible Notes under Proposed Capital Raising to Mr Gavin Evans 27 To consider and, if thought fit, pass the following resolution as an ordinary resolution of the Company: “That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, Shareholders approve the issue of such number of Shares, Options and/or Convertible Notes (and any Shares issued upon conversion of those Convertible Notes) (or any combination thereof) to Mr Gavin Evans (or his nominee), of up to a maximum value of $50,000 in aggregate, on the same terms and conditions as the Proposed Capital Raising described in the Explanatory Statement." In Favour Against Proxy’s Discretion Abstain 92,702,523 408,305 17,343,355 53,030 83.93% 0.37% 15.70% - Further Information •The Board (with Mr Evans abstaining) recommends that Shareholders vote in favour of this Resolution. •The Chair will vote undirected proxies for this Resolution. •Voting restrictions apply, as set out in the Notice of Meeting. FY25 Annual General Meeting Resolution 7: Appointment of auditor 28 To consider and, if thought fit, pass the following resolution as an ordinary resolution of the Company: “That, for the purposes of section 327B(1)(b) of the Corporations Act and for all other purposes, RSM Australia Partners be appointed as auditor of the Company, with effect from the conclusion of this Meeting." In Favour Against Proxy’s Discretion Abstain 100,739,197 9,962 17,346,269 216,202 85.30% 0.01% 14.69% - Further Information •The Board recommends that Shareholders vote in favour of this Resolution. •The Chair will vote undirected proxies for this Resolution. FY25 Annual General Meeting Resolution 8: Approval of 10% Additional Placement Capacity 29 To consider and, if thought fit, pass the following resolution as a special resolution of the Company: “That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 over a 12 month period from the date of the AGM, at an issue price of not less than that determined pursuant to Listing Rule 7.1A.3 and on the terms and conditions described in the Explanatory Statement.” In Favour Against Proxy’s Discretion Abstain 100,316,178 623,611 17,318,536 53,305 84.83% 0.53% 14.64% - Further Information •The Board recommends that Shareholders vote in favour of this Resolution. •The Chair will vote undirected proxies for this Resolution. •Voting restrictions apply, as set out in the Notice of Meeting. •For a special resolution to be passed, at least 75% of the votes validly cast on the resolution by Shareholders (by number of shares) must be in favour of the resolution. FY25 Annual General Meeting Q&A Session (Formal Session) FY25 Annual General Meeting 30 Poll & Meeting Close 31 FY25 Annual General Meeting Thank you! Thank - you